N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms
NCT ID: NCT03221231
Last Updated: 2020-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
75 participants
INTERVENTIONAL
2016-05-15
2023-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
N-acetylcysteine
N-acetylcysteine
1200 mg/day, twice daily, N-acetylcysteine
Magnetic Resonance Imaging
Neurocognitive measures
Neuro-inflammatory measures
Placebo
Placebo Oral Tablet
twice daily, placebo
Magnetic Resonance Imaging
Neurocognitive measures
Neuro-inflammatory measures
Healthy controls
Magnetic Resonance Imaging
Neurocognitive measures
Neuro-inflammatory measures
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-acetylcysteine
1200 mg/day, twice daily, N-acetylcysteine
Placebo Oral Tablet
twice daily, placebo
Magnetic Resonance Imaging
Neurocognitive measures
Neuro-inflammatory measures
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide written informed consent and to comply with study procedures.
* Dutch speaking (Dutch as primary language).
Exclusion Criteria
* History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease);
* An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (\>10 minutes), or migraine headaches;
* An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders;
* Asthma;
* Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants);
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitair Ziekenhuis Brussel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Brussels
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
F Matthys PhD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Cleo L Crunelle, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
131115
Identifier Type: -
Identifier Source: org_study_id